Targeting PCSK9 to upregulate MHCII on the surface of tumor cells in tumor immunotherapy
Số trang: 13
Loại file: pdf
Dung lượng: 4.52 MB
Lượt xem: 7
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Proprotein convertase subtilisin/kexin type 9 (PCSK9), the last member of the proprotein convertase family, functions as a classic regulator of low-density lipoprotein (LDL) by interacting with low-density lipoprotein receptor (LDLR). Recent studies have shown that PCSK9 can affect the occurrence and development of tumors and can be used as a novel therapeutic target. However, a comprehensive pan-cancer analysis of PCSK9 has yet to be conducted.
Nội dung trích xuất từ tài liệu:
Targeting PCSK9 to upregulate MHCII on the surface of tumor cells in tumor immunotherapy
Nội dung trích xuất từ tài liệu:
Targeting PCSK9 to upregulate MHCII on the surface of tumor cells in tumor immunotherapy
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Bioinformatics analysis Tumor immune microenvironment Dendritic cells Major histocompatibility complex-IIGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 169 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 139 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 110 0 0 -
12 trang 87 0 0
-
19 trang 72 0 0
-
17 trang 60 0 0
-
9 trang 36 0 0
-
11 trang 35 0 0
-
12 trang 34 0 0